# Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection

> **NCT00565539** · PHASE1 · COMPLETED · sponsor: **ZymoGenetics** · enrollment: 56 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** PEGylated recombinant interleukin 29 (PEG-rIL-29)

## Key facts

- **NCT ID:** NCT00565539
- **Lead sponsor:** ZymoGenetics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2009-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00565539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00565539, "Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00565539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*